KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis
USA - NASDAQ:KNSA - GB00BRXB0C07 - Common Stock
36.08 USD
+0.66 (+1.86%)
36.08 USD
0 (0%)
KNSA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability. KNSA is growing strongly while it is still valued neutral. This is a good combination! These ratings could make KNSA a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
KNSA had positive earnings in the past year.
In the past year KNSA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
In multiple years KNSA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of KNSA (0.72%) is better than 89.59% of its industry peers.
KNSA has a Return On Equity of 0.97%. This is amongst the best in the industry. KNSA outperforms 90.71% of its industry peers.
KNSA has a better Return On Invested Capital (0.65%) than 89.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROIC | 0.65% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.90%, KNSA belongs to the top of the industry, outperforming 90.15% of the companies in the same industry.
KNSA's Operating Margin of 0.85% is amongst the best of the industry. KNSA outperforms 89.96% of its industry peers.
With an excellent Gross Margin value of 85.93%, KNSA belongs to the best of the industry, outperforming 88.66% of the companies in the same industry.
In the last couple of years the Gross Margin of KNSA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
KNSA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, KNSA has more shares outstanding
KNSA has more shares outstanding than it did 5 years ago.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KNSA has an Altman-Z score of 9.80. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.80, KNSA belongs to the top of the industry, outperforming 85.32% of the companies in the same industry.
There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 9.8 |
ROIC/WACC0.07
WACC9.28%
2.3 Liquidity
KNSA has a Current Ratio of 3.57. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.57, KNSA perfoms like the industry average, outperforming 42.19% of the companies in the same industry.
KNSA has a Quick Ratio of 3.16. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.16, KNSA perfoms like the industry average, outperforming 40.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
KNSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.18%.
Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 122.27% on average per year.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
3.2 Future
Based on estimates for the next years, KNSA will show a very strong growth in Earnings Per Share. The EPS will grow by 47.33% on average per year.
The Revenue is expected to grow by 21.93% on average over the next years. This is a very strong growth
EPS Next Y170.9%
EPS Next 2Y116.9%
EPS Next 3Y77.75%
EPS Next 5Y47.33%
Revenue Next Year34.22%
Revenue Next 2Y35.21%
Revenue Next 3Y28.54%
Revenue Next 5Y21.93%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 902.00, KNSA can be considered very expensive at the moment.
Based on the Price/Earnings ratio, KNSA is valued cheaper than 89.59% of the companies in the same industry.
KNSA is valuated expensively when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
KNSA is valuated rather expensively with a Price/Forward Earnings ratio of 21.87.
Based on the Price/Forward Earnings ratio, KNSA is valued cheaper than 92.01% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of KNSA to the average of the S&P500 Index (22.87), we can say KNSA is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 902 | ||
| Fwd PE | 21.87 |
4.2 Price Multiples
88.85% of the companies in the same industry are more expensive than KNSA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, KNSA is valued cheaper than 93.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.21 | ||
| EV/EBITDA | 368.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
KNSA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 77.75% in the coming years.
PEG (NY)5.28
PEG (5Y)N/A
EPS Next 2Y116.9%
EPS Next 3Y77.75%
5. Dividend
5.1 Amount
No dividends for KNSA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
36.08
+0.66 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.65%
Inst Owner Change-7.48%
Ins Owners3.76%
Ins Owner Change1.73%
Market Cap2.67B
Analysts86.67
Price Target45.7 (26.66%)
Short Float %6.48%
Short Ratio4.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)141.63%
Min EPS beat(2)23.78%
Max EPS beat(2)259.48%
EPS beat(4)2
Avg EPS beat(4)-1537.64%
Min EPS beat(4)-5782.35%
Max EPS beat(4)259.48%
EPS beat(8)4
Avg EPS beat(8)-731.38%
EPS beat(12)8
Avg EPS beat(12)-432.45%
EPS beat(16)11
Avg EPS beat(16)-320.68%
Revenue beat(2)2
Avg Revenue beat(2)4.5%
Min Revenue beat(2)4.01%
Max Revenue beat(2)4.99%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)4.99%
Revenue beat(8)5
Avg Revenue beat(8)3.77%
Revenue beat(12)9
Avg Revenue beat(12)8.7%
Revenue beat(16)11
Avg Revenue beat(16)8.8%
PT rev (1m)0%
PT rev (3m)23.76%
EPS NQ rev (1m)17.77%
EPS NQ rev (3m)72.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-41.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 902 | ||
| Fwd PE | 21.87 | ||
| P/S | 5.05 | ||
| P/FCF | 40.21 | ||
| P/OCF | 39.94 | ||
| P/B | 5.4 | ||
| P/tB | 5.58 | ||
| EV/EBITDA | 368.32 |
EPS(TTM)0.04
EY0.11%
EPS(NY)1.65
Fwd EY4.57%
FCF(TTM)0.9
FCFY2.49%
OCF(TTM)0.9
OCFY2.5%
SpS7.14
BVpS6.68
TBVpS6.47
PEG (NY)5.28
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROCE | 0.82% | ||
| ROIC | 0.65% | ||
| ROICexc | 1.5% | ||
| ROICexgc | 1.61% | ||
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% | ||
| FCFM | 12.56% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 30.43% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 1120.09% | ||
| Profit Quality | 1388.12% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 9.8 |
F-Score6
WACC9.28%
ROIC/WACC0.07
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
EPS Next Y170.9%
EPS Next 2Y116.9%
EPS Next 3Y77.75%
EPS Next 5Y47.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
Revenue Next Year34.22%
Revenue Next 2Y35.21%
Revenue Next 3Y28.54%
Revenue Next 5Y21.93%
EBIT growth 1Y116.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.02%
EBIT Next 3Y109.32%
EBIT Next 5YN/A
FCF growth 1Y56.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.64%
OCF growth 3YN/A
OCF growth 5YN/A